Market news

Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascula

Amarin Corporation plc (NASDAQ:AMRN) will present new REDUCE-IT and EPA analyses at the European Society of Cardiology Congress 2026, adding further research around icosapent ethyl, cardiovascular risk factors and potential mechanisms associated with eicosapentaenoic acid. The presentations, scheduled for August 28 through August 30 during the Munich conference, will examine areas including treatment adherence, longer-term outcomes, lipoprotein(a), coagulation biomarkers and cellular pathways re

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial r

Amarin Corp PLC (AMRN) showcases international expansion and cost management success despite facing revenue declines and competitive pressures.

AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.

Amarin (NASDAQ:AMRN) said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization internationally. Management highlighted growing demand for VASCEPA in Europe, cost reductions from a completed rest

Strong international demand growth and lower operating expenses supported improved profitability metrics as Amarin reaffirmed confidence in its global commercialization strategy. Key Investor TakeawaysAmarin (NASDAQ:AMRN) reported strong international in-market demand growth, with partner network sales increasing 59% year over year despite lower reported revenue.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on Wednesday, July 29, 2026. The Company will issue a press release detailing its second quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m.

Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.